A revolutionary cardiac regeneration treatment following severe myocardial infarction

Project Key figures


days to prepare a graft


patients anticipated for the phase III clinical trial


potential patients per year in the USA, the main European countries and Japan (countries representing 1/7th of the global population)

It will soon be possible to assist cardiac muscle to auto-regenerate following a myocardial infarction. This is the objective of CellProthera, which, with the help of Bertin Technologies, has developed a unique and proprietary therapeutic concept of tissue and vascular repair of the myocardium. A glimmer of hope for the 120,000 victims of a myocardial infarction every year in France.

Regenerating the heart after a severe infarction

The start-up CellProthera has developed a treatment consisting of autologous progenitor cells obtained from a simple blood sample taken from the patient after myocardial infarction. Multiplied in vitro, they create a cellular graft, which, once directly re-injected into the infarcted area, is capable of structural and functional regeneration. Specialised in the development of innovative laboratory teams for life sciences, Bertin Technologies is the original service provider for CellProthera for the design of the first automated culture prototypes, used for producing and multiplying the cell grafts and single-use kits.

This project is currently structured around the CardioStem consortium, led by CellProthera. The objective of this collaborative project is to develop the commercial version of the StemXpand II ® cellular production machine for which Bertin Technologies is the integrator.

Avoid heavily invasive treatments

The pilot study, carried out between 2002 and 2006, showed impressive clinical results in the seven patients treated and, amongst other things, enabled cardiac transplantation to be avoided in three of these patients. Promising figures for very high stakes given that 120,000 myocardial infarctions occur every year in France. CellProthera has commenced clinical trials using the first version of the machine, developed with the help of Bertin Technologies. In view of its future marketing, a phase III study will subsequently be rolled out in Europe and North America.